PD – L1 Biomarker Testing Market Snapshot

The global PD – L1 biomarker testing market holds a valuation of US$ 597.9 Million by the end of the year 2022. Throughout the forecast period of 2023 to 2033, the market is likely to display growth at a CAGR of 9.14%, and is expected to hold a market value of around US$ 1.58 Billion in 2033.

Market Outlook

Data Points Market Insights
Market Value 2022 US$ 597.9 Million
Market Value 2023 US$ 659.6 Million
Market Value 2033 US$ 1.58 Billion
CAGR 2023 to 2033 9.14%
Market Share of Top 5 Countries (2022) 75.8%
Key Market Players F. Hoffmann - La Roche Ltd., Agilent Technologies, Inc., Abcam plc, Shuwein Biotech Co. Ltd., NeoGenomics Laboratories, Inc., HalioDx, Abcam plc, Merck, Bristol-Myers Squibb, AstraZeneca

Cancer diagnostics involves detection of specific biomarkers, proteins, and symptoms of cancers in patients that indicate the development of abnormal cancerous cells. The detection make use of specific technology and devices used in its diagnosis. PD-L1 is a protein that helps to keep the immune system in check. In cancerous conditions, this protein is found in higher concentrations.

Cancer has a significant impact on society worldwide. It is one of the world's leading causes of death, with a higher prevalence in developed and emerging markets. According to the article published in a cancer journal for clinicians in 2021 regarding global cancer statistics 2020, International Agency for Research on Cancer estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020 in 185 countries. The alarming rise in cancer prevalence requires healthcare providers to reconsider cancer treatment goals and shift their focus to preventive care.

Rising research activities for the treatment of several cancer indications are expected to bode well for the market. Increasing applications of biomarker testing across abundant tumour types, including an earlier-stage cancer detection is anticipated to provide opportunities for key players to invest and research in the biomarker testing market. The innovation of biomarker testing is finding a new niche in cancer immunotherapy, which will help the market expand.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis from 2017 to 2022 Vs Market Outlook for 2023 to 2033 for PD – L1 Biomarker Testing Market

The PD – L1 biomarker testing market expanded at a CAGR of 6.96% between 2017 and 2022 due to increased awareness of cancer disease, advanced technologies used for cancer diagnosis.

The market value for PD-L1 biomarker testing market was around 1.0% of the overall US$ 67.2 Billion of the global diagnostic biomarkers market in 2022.

PD-L1 biomarker testing is a reliable diagnostic approach in cancer management since it is based on the fact that each person has distinctive levels of the PD-L1 protein. For instance, early stages of non-small cell lung cancer (NSCLC) and melanoma are found using PD-L1 biomarkers in cancer diagnoses and analysis.

The growing availability of high-quality immunotherapy products worldwide is addressing unmet cancer treatment needs. In the current scenario, lifestyle changes such as physical inactivity, tobacco consumption and smoking, as well as an unhealthy diet, are main contributors to the rising burden of cancerous indications.

Key market players are focusing on the development or extension of novel biologics using existing biologic resources for innovative product identification and the provision of patented therapies. Cancer immunotherapy has advanced the diagnostic approach to cancer detection and management, propelling the PD-L1 biomarker testing market forward.

H1-H2 Update

Market Statistics Details
Jan to Jun (H1), 2021 (A) 8.30%
Jul to Dec (H2), 2021 (A) 12.06%
Jan to Jun (H1),2022 Projected (P) 8.27%
Jan to Jun (H1),2022 Outlook (O) 9.11%
Jul to Dec (H2), 2022 Outlook (O) 11.69%
Jul to Dec (H2), 2022 Projected (P) 11.06%
Jan to Jun (H1), 2023 Projected (P) 8.30%
BPS Change : H1,2022 (O) - H1,2022 (P) 85↑
BPS Change : H1,2022 (O) - H1,2021 (A) 82↑
BPS Change: H2, 2022 (O) - H2, 2022 (P) 63↑
BPS Change: H2, 2022 (O) - H2, 2022 (A) (-) 37↓
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Key Drivers for PD – L1 Biomarker Testing Product Manufacturers?

Increasing number of cancer cases worldwide is the key driver to boost the global market. Cancer is at the second place for prevalence in the world. According to World Cancer Research Fund International, detected cancer cases were 18,094,716 million globally in 2020. Prevention of cancer is very challenging and needs an early detection.

The development of reliable PD-L1 biomarker testing with appropriate licensing for use is expected to drive PD-L1 biomarker testing sales in the coming years. Because of PD-L1 biomarker screening tests, the pharmacological diagnosis of cancer were possible. It is helping in production of personalised medicines, thus anticipated to increase the cancer screening biomarkers like PD-L1 biomarker.

The lifestyle choices, dietary habits, and social factors like drinking, smoking, and tobacco habits have dramatically increased in recent years all throughout the world, especially among younger generations. These factors directly adds to the rising incidence of lung cancer around the world. People's awareness of early detection and diagnosis of lung cancer has grown in recent years, and more people are undergoing such tests. This, too, is expected to benefit the market in the forecast period.

What are the Factors Restraining Demand for PD – L1 Biomarker Testing Products?

The challenges in testing and identifying biomarkers, as well as their validation and implementation in molecular diagnostics, are factors limiting the demand for PD-L1 biomarker testing. Trials including clone evolution, tumour heterogeneity detection, and biomarker testing are also likely to have a detrimental effect on market expansion.

The growth of the PD-L1 biomarker testing market is also hampered by the lack of skilled laboratory technicians because diagnostic laboratories use cutting-edge technology and automation. Despite the availability of advanced tools that make testing simple, critical mistakes regarding the dependability of data across multiple platform, as well as comparable difficulties in analytical validation, will affect sales.

Molecular testing faces considerable obstacles in several regions due to difficulties with regulatory authorities' drug licencing and testing procedures as well as the availability of constrained reimbursement. These characteristics favour on-demand testing, which is expected to restrain the market's expansion for PD-L1 biomarker testing in the years to come.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Insights

Country The USA
Market Share (2023) 54.3%
Market Share (2033) 57.4%
BPS Analysis 311
Country The United kingdom
Market Share (2023) 6.8%
Market Share (2033) 7.3%
BPS Analysis 46
Country Canada
Market Share (2023) 5.6%
Market Share (2033) 4.1%
BPS Analysis -148
Country Germany
Market Share (2023) 5.2%
Market Share (2033) 4.7%
BPS Analysis -54
Country China
Market Share (2023) 4.5%
Market Share (2033) 5.2%
BPS Analysis 70

What is Driving the USA Market?

In 2023, with 54.3% of the market share, the United States will dominate the global market. The country's high prevalence of lung cancer and related chronic illnesses, as well as rising investments in the production of cutting-edge medications, medical technology in the oncology market, and increasing attention on early cancer diagnosis will aid the USA  market grow throughout the duration of the forecast period.

According to American Cancer Society, the estimated values for lung cancer in the USA in 2023 are 238,340 new cases of lung cancer about and about 127,070 deaths from lung cancer.

Why is the United kingdom Market Considered Lucrative?

TheUnited kingdom market is anticipated to expand at a 9.9% CAGR over the forecast period, accounting for a significant part of the market for increased PD-L1 testing in the Europe.

Sales in the market are expected to be boosted by the presence of governed predictive testing within the nation under national and regional regulations, awareness of early cancer diagnosis, and technological development. Increasing medical tourism in the United kingdom will further increase the demand for PD-L1 biomarker testing.

According to Cancer Research United kingdom, estimated 167,000 cancer deaths occur in the United kingdom each year due to the high frequency of the disease.

What Makes the China Market Attractive?

PD-L1 biomarker testing market in China will expand at a CAGR of 10.8% over the forecast period. The need for PD-L1 biomarker testing is being driven by an increase in cancer cases in the nation.

According statistical presentation by GLOBOCAN 2022, there were approximately 4,820,000 new cancer cases identified in China in 2022. Among this number, 2,625,070 men and 2,195,764 women were diagnosed. These metrics support the transitive efforts by the country to present biomarker testing into the overall healthcare structure.

Category-wise Insights

Which PD-L1 Biomarker Testing Product is Considered Highly Sought-After?

PD-L1 22C3 assay kit demand will hold 49.90% of the overall market share in 2023. Sales in this market will grow during the forecast period due to the efficiency of PD-L1 22C3 tests used in non-small cell lung cancer testing and patients' positive responses to immune checkpoint inhibitors.

Why are Sales of PD-L1 Biomarker Testing in NSCLC Rising?

Global demand for PD-L1 Biomarker Testing for NSCLC is growing as lung cancer incidence rises. In 2023, the category is set to hold 62.8% of the global market share, and it is anticipated that this pattern will hold in the upcoming years. The availability of PD-L1 protein is the only biomarker, which can guide treatment with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).

Which End User Benefits the Most by PD-L1 Biomarker Testing?

In terms of end users, 44.1% of the global market share in 2023 will be held by cancer research institutes. The study and development of innovative treatments for oncological purposes across various cancer research centers is gaining traction as the prevalence of cancer-related morbidity increases globally.

Comparative View of Adjacent PD – L1 Biomarker Testing Market

PD - L1 Biomarker Testing Market:

Attributes PD - L1 Biomarker Testing Market
CAGR (2023 to 2033) 9.14%
Market Value (2023) US$ 659.6 Million
Growth Factor Increased awareness of cancer diagnosis, cancer diagnosis technological development, and increased biomarker testing utilization.
Key Market Trend The development of reliable cancer screening and laboratory-based tests that provide timely diagnosis will benefit the market

PD1 Non-Small Cell Lung Cancer Treatment Market:

Attributes PD1 Non-Small Cell Lung Cancer Treatment Market
CAGR (2023 to 2033) 8.51%
Market Value (2023) US$ 26.96 Billion
Growth Factor High growth is attributed to the growing patient population, expected entry of several drugs, and increasing investment by industry players in research and development of NSCLC therapy
Key Trend Distinct clinical benefits offered by therapy such as minimal side effects along with availability of number of targeted therapeutics

Cardiac Biomarker Diagnostic Test Kits Market Snapshot:

Attributes Cardiac Biomarker Diagnostic Test Kits Market Snapshot
CAGR (2023 to 2033) 5.0%
Market Value (2023) US$ 1.89 Billion
Growth Factor Growing prevalence of cardiac diseases, introducing new products and huge investments in research and development to develop advanced cardiac biomarkers
Key Trend Favorable government initiatives, health professionals and private organizations are introducing and establishing diagnostic laboratories, collaborating with leading players

Competitive Landscape

The focus of key players is on the development and introduction of novel PD-L1 biomarkers for the treatment of various cancers. Market exclusivity and government incentives to promote new and innovative options for cancer treatment will create lucrative opportunities for market players.

Some recent developments include

  • In June 2020, Merck received the FDA approval for second application for KEYTRUDA® (pembrolizumab), for the treatment of patients of all age groups suffering from metastatic tumour mutational burden-high (TMB-H).
  • In May 2020, Agilent Technologies' PD-L1 IHC 28-8 pharmDx was approved by the FDA for diagnosis of NSCLC.

Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the PD-L1 Biomarker Testing market, which are available in the full report.

Report Scope as Per PD – L1 Biomarker Testing Industry Analysis

Attribute Details
Forecast Period 2023 to 2033
Historical Data Available for 2017 to 2022
Market Analysis US$ Million for Value, and Units for Volume
Key Regions Covered North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa (MEA)
Key Countries Covered USA, Canada, Brazil, Mexico, Argentina, United kingdom, Germany, Italy, France, Spain, Russia, BENELUX, China, Japan, South Korea, India, Indonesia, Malaysia, Thailand, Australia, New Zealand, GCC countries, Türkiye, South Africa and North Africa.
Key Market Segments Covered Product, Type, Application, and Region
Key Companies Profiled
  • F. Hoffmann – La Roche Ltd.
  • Agilent Technologies, Inc.
  • Abcam plc, Shuwein Biotech Co. Ltd.
  • NeoGenomics Laboratories, Inc.
  • HalioDx, Abcam plc
  • Merck, Bristol-Myers Squibb
  • AstraZeneca
Report Coverage Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Pricing Available upon Request

Key Market Segments Covered in PD – L1 Biomarker Testing Industry Research

By Product:

  • PD-L1 22C3 Assay Kit
  • PD-L1 28-8 Assay Kit
  • PD-L1 SP142 Assay Kit
  • PD-L1 263 Assay Kit

By Indication:

  • NSCLC
  • Melanoma
  • Renal Cell Carcinoma
  • Gastrointestinal tract Malignancy
  • Haematological Malignancies
  • Ovarian Cancer
  • Other

By End User:

  • Hospitals
  • Diagnostic Laboratories
  • Cancer Research Institutes

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East and Africa (MEA)

Frequently Asked Questions

What is the Current Market Valuation?

The market in 2023 is valued at US$ 659.6 Million

How Big will the PD-L1 Biomarker Testing Market by 2033?

By 2033, the market is expected to reach US$ 1.58 Billion

What is the Growth Rate of the Market Through 2033?

The market is likely to expand at a 9.14% CAGR through 2033.

How was the Historical Performance of the Market?

From 2018 to 2022, the market record a 6.96% CAGR.

What is the United States Market Outlook in 2023?

In 2023, the United States accounts for 54.3% revenue.

Table of Content

1. Executive Summary | PD-L1 Biomarker Testing Market

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Market Innovation / Development Trends

4. Key Success Factors

    4.1. Product Adoption/Usage Analysis

    4.2. Key Promotional Strategies, by Manufacturers

    4.3. Key Regulations

    4.4. PESTEL Analysis

    4.5. Porter’s Analysis

    4.6. Value Chain Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare Outlook

        5.1.3. Global Diagnostic Biomarkers Overview

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Top Companies Historical Growth

        5.2.2. New Product Launches and Approvals

        5.2.3. Adoption rate of Cancer Immunotherapy

        5.2.4. Increasing R&D Expenditure by Key Players

        5.2.5. Strategic Collaborations among Players

        5.2.6. Pipeline Assessment

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

    6.1. COVID-19 and Impact Analysis

        6.1.1. By Product

        6.1.2. By Indication

        6.1.3. By End User

        6.1.4. By Country

    6.2. 2022 Market Scenario

7. Global Market Volume (Units) Analysis 2017 to 2022 and Forecast, 2023 to 2033

    7.1. Historical Market Volume (Units) Analysis, 2017 to 2022

    7.2. Current and Future Market Volume (Units) Projections, 2023 to 2033

        7.2.1. Y-o-Y Growth Trend Analysis

8. Global Market - Pricing Analysis

    8.1. Regional Pricing Analysis By Material

    8.2. Pricing Break-up

        8.2.1. Manufacturer Level Pricing

        8.2.2. Distributor Level Pricing

    8.3. Global Average Pricing Analysis Benchmark

    8.4. Pricing Assumptions

9. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033

    9.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022

    9.2. 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033

        9.2.1. Y-o-Y Growth Trend Analysis

        9.2.2. Absolute $ Opportunity Analysis

10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Product, 2017 to 2022

    10.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Product, 2023 to 2033

        10.3.1. PD – L1 22C3 Assay Kit

        10.3.2. PD – L1 28 – 8 Assay Kit

        10.3.3. PD – L1 SP142 Assay Kit

        10.3.4. PD – L1 263 Assay Kit

    10.4. Market Attractiveness Analysis by Product

11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Million) Analysis by Indication, 2017 to 2022

    11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Indication, 2023 to 2033

        11.3.1. NSCLS

        11.3.2. Melanoma

        11.3.3. Renal Cell Carcinoma

        11.3.4. Gastrointestinal Tract Malignancy

        11.3.5. Hematological Malignancies

        11.3.6. Ovarian Cancer

        11.3.7. Other

    11.4. Market Attractiveness Analysis by Indication

12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Million) Analysis by End User, 2017 to 2022

    12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by End User, 2023 to 2033

        12.3.1. Hospitals

        12.3.2. Diagnostic Laboratories

        12.3.3. Cancer Research Institutes

    12.4. Market Attractiveness Analysis by End User

13. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region

    13.1. Introduction / Key Findings

    13.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, by Region, 2017 to 2022

    13.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis Forecast by Region, 2023 to 2033

        13.3.1. North America

        13.3.2. Latin America

        13.3.3. Europe

        13.3.4. East Asia

        13.3.5. South Asia

        13.3.6. Oceania

        13.3.7. Middle East and Africa

    13.4. Market Attractiveness Analysis by Region

14. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    14.1. Introduction

    14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022

    14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033

        14.3.1. By Country

            14.3.1.1. USA

            14.3.1.2. Canada

        14.3.2. By Product

        14.3.3. By Indication

        14.3.4. By End User

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Product

        14.4.3. By Indication

        14.4.4. By End User

    14.5. Market Trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

    14.8. Country Level Analysis & Forecast

        14.8.1. USA Market

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast by Market Taxonomy

                14.8.1.2.1. By Product

                14.8.1.2.2. By Indication

                14.8.1.2.3. By End User

        14.8.2. Canada Market

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast by Market Taxonomy

                14.8.2.2.1. By Product

                14.8.2.2.2. By Indication

                14.8.2.2.3. By End User

15. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    15.1. Introduction

    15.2. Historical Market Size (US$ Million) and Volume (Units) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022

    15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033

        15.3.1. By Country

            15.3.1.1. Mexico

            15.3.1.2. Brazil

            15.3.1.3. Argentina

            15.3.1.4. Rest of Latin America

        15.3.2. By Product

        15.3.3. By Indication

        15.3.4. By End User

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Product

        15.4.3. By Indication

        15.4.4. By End User

    15.5. Market Trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

    15.8. Country Level Analysis & Forecast

        15.8.1. Mexico Market Analysis

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast by Market Taxonomy

                15.8.1.2.1. By Product

                15.8.1.2.2. By Indication

                15.8.1.2.3. By End User

        15.8.2. Brazil Market Analysis

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast by Market Taxonomy

                15.8.2.2.1. By Product

                15.8.2.2.2. By Indication

                15.8.2.2.3. By End User

        15.8.3. Argentina Market Analysis

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast by Market Taxonomy

                15.8.3.2.1. By Product

                15.8.3.2.2. By Indication

                15.8.3.2.3. By End User

16. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    16.1. Introduction

    16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022

    16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033

        16.3.1. By Country

            16.3.1.1. Germany

            16.3.1.2. Italy

            16.3.1.3. France

            16.3.1.4. United kingdom

            16.3.1.5. Spain

            16.3.1.6. BENELUX

            16.3.1.7. Russia

            16.3.1.8. Rest of Europe

        16.3.2. By Product

        16.3.3. By Indication

        16.3.4. By End User

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Product

        16.4.3. By Indication

        16.4.4. By End User

    16.5. Market Trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

    16.8. Country Level Analysis & Forecast

        16.8.1. Germany Market Analysis

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast by Market Taxonomy

                16.8.1.2.1. By Product

                16.8.1.2.2. By Indication

                16.8.1.2.3. By End User

        16.8.2. Italy Market Analysis

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast by Market Taxonomy

                16.8.2.2.1. By Product

                16.8.2.2.2. By Indication

                16.8.2.2.3. By End User

        16.8.3. France Market Analysis

            16.8.3.1. Introduction

            16.8.3.2. Market Analysis and Forecast by Market Taxonomy

                16.8.3.2.1. By Product

                16.8.3.2.2. By Indication

                16.8.3.2.3. By End User

        16.8.4. United kingdom Market Analysis

            16.8.4.1. Introduction

            16.8.4.2. Market Analysis and Forecast by Market Taxonomy

                16.8.4.2.1. By Product

                16.8.4.2.2. By Indication

                16.8.4.2.3. By End User

        16.8.5. Spain Market Analysis

            16.8.5.1. Introduction

            16.8.5.2. Market Analysis and Forecast by Market Taxonomy

                16.8.5.2.1. By Product

                16.8.5.2.2. By Indication

                16.8.5.2.3. By End User

        16.8.6. BENELUX Market Analysis

            16.8.6.1. Introduction

            16.8.6.2. Market Analysis and Forecast by Market Taxonomy

                16.8.6.2.1. By Product

                16.8.6.2.2. By Indication

                16.8.6.2.3. By End User

        16.8.7. Russia Market Analysis

            16.8.7.1. Introduction

            16.8.7.2. Market Analysis and Forecast by Market Taxonomy

                16.8.7.2.1. By Product

                16.8.7.2.2. By Indication

                16.8.7.2.3. By End User

17. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    17.1. Introduction

    17.2. Historical Market Size (US$ Million) and Volume (Units) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022

    17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033

        17.3.1. By Country

            17.3.1.1. China

            17.3.1.2. Japan

            17.3.1.3. South Korea

        17.3.2. By Product

        17.3.3. By Indication

        17.3.4. By End User

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Product

        17.4.3. By Indication

        17.4.4. By End User

    17.5. Market Trends

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

    17.8. Country Level Analysis & Forecast

        17.8.1. China Market Analysis

            17.8.1.1. Introduction

            17.8.1.2. Market Analysis and Forecast by Market Taxonomy

                17.8.1.2.1. By Product

                17.8.1.2.2. By Indication

                17.8.1.2.3. By End User

        17.8.2. Japan Market Analysis

            17.8.2.1. Introduction

            17.8.2.2. Market Analysis and Forecast by Market Taxonomy

                17.8.2.2.1. By Product

                17.8.2.2.2. By Indication

                17.8.2.2.3. By End User

        17.8.3. South Korea Market Analysis

            17.8.3.1. Introduction

            17.8.3.2. Market Analysis and Forecast by Market Taxonomy

                17.8.3.2.1. By Product

                17.8.3.2.2. By Indication

                17.8.3.2.3. By End User

18. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    18.1. Introduction

    18.2. Historical Market Size (US$ Million) and Volume (Units) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022

    18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033

        18.3.1. By Country

            18.3.1.1. India

            18.3.1.2. Indonesia

            18.3.1.3. Malaysia

            18.3.1.4. Thailand

            18.3.1.5. Rest of South Asia

        18.3.2. By Product

        18.3.3. By Indication

        18.3.4. By End User

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Product

        18.4.3. By Indication

        18.4.4. By End User

    18.5. Market Trends

    18.6. Key Market Participants - Intensity Mapping

    18.7. Drivers and Restraints - Impact Analysis

    18.8. Country Level Analysis & Forecast

        18.8.1. India Market Analysis

            18.8.1.1. Introduction

            18.8.1.2. Market Analysis and Forecast by Market Taxonomy

                18.8.1.2.1. By Product

                18.8.1.2.2. By Indication

                18.8.1.2.3. By End User

        18.8.2. Indonesia Market Analysis

            18.8.2.1. Introduction

            18.8.2.2. Market Analysis and Forecast by Market Taxonomy

                18.8.2.2.1. By Product

                18.8.2.2.2. By Indication

                18.8.2.2.3. By End User

        18.8.3. Malaysia Market Analysis

            18.8.3.1. Introduction

            18.8.3.2. Market Analysis and Forecast by Market Taxonomy

                18.8.3.2.1. By Product

                18.8.3.2.2. By Indication

                18.8.3.2.3. By End User

        18.8.4. Thailand Market Analysis

            18.8.4.1. Introduction

            18.8.4.2. Market Analysis and Forecast by Market Taxonomy

                18.8.4.2.1. By Product

                18.8.4.2.2. By Indication

                18.8.4.2.3. By End User

19. Oceania Market 2017 to 2022 and Forecast 2023 to 2033

    19.1. Introduction

    19.2. Historical Market Size (US$ Million) and Volume (Units) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022

    19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033

        19.3.1. By Country

            19.3.1.1. Australia

            19.3.1.2. New Zealand

        19.3.2. By Product

        19.3.3. By Indication

        19.3.4. By End User

    19.4. Market Attractiveness Analysis

        19.4.1. By Country

        19.4.2. By Product

        19.4.3. By Indication

        19.4.4. By End User

    19.5. Market Trends

    19.6. Key Market Participants - Intensity Mapping

    19.7. Drivers and Restraints - Impact Analysis

    19.8. Country Level Analysis & Forecast

        19.8.1. Australia Market Analysis

            19.8.1.1. Introduction

            19.8.1.2. Market Analysis and Forecast by Market Taxonomy

                19.8.1.2.1. By Product

                19.8.1.2.2. By Indication

                19.8.1.2.3. By End User

        19.8.2. New Zealand Market Analysis

            19.8.2.1. Introduction

            19.8.2.2. Market Analysis and Forecast by Market Taxonomy

                19.8.2.2.1. By Product

                19.8.2.2.2. By Indication

                19.8.2.2.3. By End User

20. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    20.1. Introduction

    20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022

    20.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033

        20.3.1. By Country

            20.3.1.1. GCC Countries

            20.3.1.2. Türkiye

            20.3.1.3. North Africa

            20.3.1.4. South Africa

            20.3.1.5. Rest of Middle East and Africa

        20.3.2. By Product

        20.3.3. By Indication

        20.3.4. By End User

    20.4. Market Attractiveness Analysis

        20.4.1. By Country

        20.4.2. By Product

        20.4.3. By Indication

        20.4.4. By End User

    20.5. Market Trends

    20.6. Key Market Participants - Intensity Mapping

    20.7. Drivers and Restraints - Impact Analysis

    20.8. Country Level Analysis & Forecast

        20.8.1. GCC Countries Market Analysis

            20.8.1.1. Introduction

            20.8.1.2. Market Analysis and Forecast by Market Taxonomy

                20.8.1.2.1. By Product

                20.8.1.2.2. By Indication

                20.8.1.2.3. By End User

        20.8.2. Türkiye Market Analysis

            20.8.2.1. Introduction

            20.8.2.2. Market Analysis and Forecast by Market Taxonomy

                20.8.2.2.1. By Product

                20.8.2.2.2. By Indication

                20.8.2.2.3. By End User

        20.8.3. South Africa Market Analysis

            20.8.3.1. Introduction

            20.8.3.2. Market Analysis and Forecast by Market Taxonomy

                20.8.3.2.1. By Product

                20.8.3.2.2. By Indication

                20.8.3.2.3. By End User

        20.8.4. North Africa Market Analysis

            20.8.4.1. Introduction

            20.8.4.2. Market Analysis and Forecast by Market Taxonomy

                20.8.4.2.1. By Product

                20.8.4.2.2. By Indication

                20.8.4.2.3. By End User

21. Market Structure Analysis

    21.1. Market Analysis by Tier of Companies

    21.2. Market Share Analysis of Top Players

    21.3. Market Presence Analysis

22. Competition Analysis

    22.1. Competition Dashboard

    22.2. Competition Benchmarking

    22.3. Competition Deep Dive

        22.3.1. F. Hoffmann – La Roche Ltd.

            22.3.1.1. Overview

            22.3.1.2. Product Portfolio

            22.3.1.3. Sales Footprint

            22.3.1.4. Key Financials

            22.3.1.5. SWOT Analysis

            22.3.1.6. Key Developments

            22.3.1.7. Strategy Overview

                22.3.1.7.1. Marketing Strategy

                22.3.1.7.2. Product Strategy

                22.3.1.7.3. Channel Strategy

        22.3.2. Agilent Technologies, Inc.

            22.3.2.1. Overview

            22.3.2.2. Product Portfolio

            22.3.2.3. Sales Footprint

            22.3.2.4. Key Financials

            22.3.2.5. SWOT Analysis

            22.3.2.6. Key Developments

            22.3.2.7. Strategy Overview

                22.3.2.7.1. Marketing Strategy

                22.3.2.7.2. Product Strategy

                22.3.2.7.3. Channel Strategy

        22.3.3. Abcam plc

            22.3.3.1. Overview

            22.3.3.2. Product Portfolio

            22.3.3.3. Sales Footprint

            22.3.3.4. Key Financials

            22.3.3.5. SWOT Analysis

            22.3.3.6. Key Developments

            22.3.3.7. Strategy Overview

                22.3.3.7.1. Marketing Strategy

                22.3.3.7.2. Product Strategy

                22.3.3.7.3. Channel Strategy

        22.3.4. Shuwein Biotech Co. Ltd.

            22.3.4.1. Overview

            22.3.4.2. Product Portfolio

            22.3.4.3. Sales Footprint

            22.3.4.4. Key Financials

            22.3.4.5. SWOT Analysis

            22.3.4.6. Key Developments

            22.3.4.7. Strategy Overview

                22.3.4.7.1. Marketing Strategy

                22.3.4.7.2. Product Strategy

                22.3.4.7.3. Channel Strategy

        22.3.5. NeoGenomics Laboratories, Inc.

            22.3.5.1. Overview

            22.3.5.2. Product Portfolio

            22.3.5.3. Sales Footprint

            22.3.5.4. Key Financials

            22.3.5.5. SWOT Analysis

            22.3.5.6. Key Developments

            22.3.5.7. Strategy Overview

                22.3.5.7.1. Marketing Strategy

                22.3.5.7.2. Product Strategy

                22.3.5.7.3. Channel Strategy

        22.3.6. HalioDx

            22.3.6.1. Overview

            22.3.6.2. Product Portfolio

            22.3.6.3. Sales Footprint

            22.3.6.4. Key Financials

            22.3.6.5. SWOT Analysis

            22.3.6.6. Key Developments

            22.3.6.7. Strategy Overview

                22.3.6.7.1. Marketing Strategy

                22.3.6.7.2. Product Strategy

                22.3.6.7.3. Channel Strategy

        22.3.7. Abcam plc

            22.3.7.1. Overview

            22.3.7.2. Product Portfolio

            22.3.7.3. Sales Footprint

            22.3.7.4. Key Financials

            22.3.7.5. SWOT Analysis

            22.3.7.6. Key Developments

            22.3.7.7. Strategy Overview

                22.3.7.7.1. Marketing Strategy

                22.3.7.7.2. Product Strategy

                22.3.7.7.3. Channel Strategy

        22.3.8. Merck

            22.3.8.1. Overview

            22.3.8.2. Product Portfolio

            22.3.8.3. Sales Footprint

            22.3.8.4. Key Financials

            22.3.8.5. SWOT Analysis

            22.3.8.6. Key Developments

            22.3.8.7. Strategy Overview

                22.3.8.7.1. Marketing Strategy

                22.3.8.7.2. Product Strategy

                22.3.8.7.3. Channel Strategy

        22.3.9. Bristol-Myers Squibb

            22.3.9.1. Overview

            22.3.9.2. Product Portfolio

            22.3.9.3. Sales Footprint

            22.3.9.4. Key Financials

            22.3.9.5. SWOT Analysis

            22.3.9.6. Key Developments

            22.3.9.7. Strategy Overview

                22.3.9.7.1. Marketing Strategy

                22.3.9.7.2. Product Strategy

                22.3.9.7.3. Channel Strategy

        22.3.10. AstraZeneca

            22.3.10.1. Overview

            22.3.10.2. Product Portfolio

            22.3.10.3. Sales Footprint

            22.3.10.4. Key Financials

            22.3.10.5. SWOT Analysis

            22.3.10.6. Key Developments

            22.3.10.7. Strategy Overview

                22.3.10.7.1. Marketing Strategy

                22.3.10.7.2. Product Strategy

                22.3.10.7.3. Channel Strategy

23. Assumptions and Acronyms Used

24. Research Methodology

Recommendations

Healthcare

Renal Biomarker Market

November 2016

REP-GB-1731

April 2024

250 pages

Healthcare

Cancer Diagnostics Market

March 2021

REP-GB-1090

August 2023

315 pages

Healthcare

Diagnostic Exosome Biomarkers Market

November 2017

REP-GB-5564

August 2023

324 pages

Explore Healthcare Insights

View Reports
Future Market Insights

PD-L1 Biomarker Testing Market